Conduit Pharmaceuticals (FRA:ZK7) Net Income From Continuing Operations : €-17.88 Mil (TTM As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Conduit Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Conduit Pharmaceuticals's net income from continuing operations for the three months ended in Mar. 2025 was €-4.76 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was €-17.88 Mil.

Conduit Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for Conduit Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conduit Pharmaceuticals Net Income From Continuing Operations Chart

Conduit Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

-3.24

-4.61

-0.49

-17.00

Conduit Pharmaceuticals Quarterly Data
	Dec21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income From Continuing Operations	Get a 7-Day Free Trial								-3.27	-5.00	-5.82	-2.30	-4.76

Conduit Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-17.88 Mil.

Conduit Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (FRA:ZK7) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

CDT:USA

Address

4581 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103

Website

https://www.conduitpharma.com

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Conduit Pharmaceuticals Headlines

No Headlines